[go: up one dir, main page]

WO2007072491A3 - Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same - Google Patents

Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same Download PDF

Info

Publication number
WO2007072491A3
WO2007072491A3 PCT/IN2005/000425 IN2005000425W WO2007072491A3 WO 2007072491 A3 WO2007072491 A3 WO 2007072491A3 IN 2005000425 W IN2005000425 W IN 2005000425W WO 2007072491 A3 WO2007072491 A3 WO 2007072491A3
Authority
WO
WIPO (PCT)
Prior art keywords
17beta
estradiol
heart disease
coronary
micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2005/000425
Other languages
French (fr)
Other versions
WO2007072491A2 (en
Inventor
Baskaran Chandrasekar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/IN2005/000425 priority Critical patent/WO2007072491A2/en
Publication of WO2007072491A2 publication Critical patent/WO2007072491A2/en
Publication of WO2007072491A3 publication Critical patent/WO2007072491A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to a method of treating ischemic heart disease by stimulating arteriogenesis and angiogenesis. This is achieved by intracoronary administration of a sustained release pharmaceutical formulation containing 17beta-estradiol microencapsulated in biodegradable polymers. A method for stimulation of arteriogenesis and angiogenesis in severe ischemic heart disease by the intra-coronary administration of 17beta-estradiol is described. The 17beta-estradiol is delivered preferably in the form of encapsulated bio-degradable micro-spheres. Intra-coronary delivery of 17beta-estradiol - loaded microspheres can be easily performed during the procedure of cardiac catheterization. The administered 17beta-estradiol - loaded micro-spheres become trapped in the coronary micro-circulation, and undergo gradual degradation producing a sustained concentration of 17beta-estradiol at the level of coronary micro-circulation.
PCT/IN2005/000425 2005-12-21 2005-12-21 Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same Ceased WO2007072491A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2005/000425 WO2007072491A2 (en) 2005-12-21 2005-12-21 Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2005/000425 WO2007072491A2 (en) 2005-12-21 2005-12-21 Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same

Publications (2)

Publication Number Publication Date
WO2007072491A2 WO2007072491A2 (en) 2007-06-28
WO2007072491A3 true WO2007072491A3 (en) 2007-11-08

Family

ID=38189081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000425 Ceased WO2007072491A2 (en) 2005-12-21 2005-12-21 Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same

Country Status (1)

Country Link
WO (1) WO2007072491A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643604A (en) * 1990-06-14 1997-07-01 Aplicaciones Farmaceuticas S.A. De C.V. Parenteral dosage form
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5643604A (en) * 1990-06-14 1997-07-01 Aplicaciones Farmaceuticas S.A. De C.V. Parenteral dosage form
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity

Also Published As

Publication number Publication date
WO2007072491A2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
JP5881606B2 (en) Preparation for spinal cord injury treatment
DE69824231T2 (en) Bioadhesive tablets
US9597436B2 (en) Advanced heart failure treatment material as myocardial/cardiovascular regeneration device
JP5628467B2 (en) Biodegradable sustained release drug delivery system
Jin et al. Radiosensitization of paclitaxel, etanidazole and paclitaxel+ etanidazole nanoparticles on hypoxic human tumor cells in vitro
ES2384641T3 (en) Lipolytic formulation that enhances the release maintained for the localized treatment of adipose tissue
TWI343263B (en) Patches for mucosa of oral cavity containing fentanyl
US11896598B2 (en) Appetite suppressant compositions and methods thereof
KR20130114240A (en) Nanoparticles loaded with chemotherapeutic antitumoral drug
HUE026994T2 (en) Liquid nasal spray containing low-dose naltrexone
Larrañeta et al. Overview of the clinical current needs and potential applications for long-acting and implantable delivery systems
Angamuthu et al. Controlled-release injectable containing Terbinafine/PLGA microspheres for Onychomycosis Treatment
US20160045439A1 (en) Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same
WO2009116556A1 (en) Pharmaceutical composition for injection
RU2010110658A (en) COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC DISEASES
WO2004006929A1 (en) Composition for nasal absorption
JP2011519946A (en) 1-methylnicotinamide analogues
Sahu et al. Nanofibers in drug delivery
WO2007072491A3 (en) Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same
CA3074541C (en) Appetite suppressant compositions and methods thereof
Yao et al. Nano-particle engineered atorvastatin delivery to support mesenchymal stem cell survival in infarcted myocardium
US20140005199A1 (en) Implant for the controlled release of pharmaceutically active agents
EP4406530A1 (en) Dosage form for intra-articular injection comprising colchicine for use in the treatment of a joint disease such as osteoarthritis
Santos et al. Natural-based biomaterials for drug delivery wound healing patches
WO2008010768A1 (en) Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05849953

Country of ref document: EP

Kind code of ref document: A2